Suicidal Ideation, Behaviors Not Increased With GLP-1 RAs for Seniors With T2D

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on July 16, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, July 16, 2024 -- For older adults with type 2 diabetes (T2D), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is not associated with a significantly increased risk for suicidal ideation and behaviors, according to a study published online July 16 in the Annals of Internal Medicine.

Huilin Tang, from the University of Florida College of Pharmacy in Gainesville, and colleagues examined the association between GLP-1 RAs versus sodium-glucose cotransporter 2 inhibitors (SGLT2is) or dipeptidyl peptidase 4 inhibitors (DPP4is) and the risk for suicidal ideation and behaviors among older adults with T2D in two target trial emulation studies using U.S. national Medicare administrative data from January 2017 to December 2020. In each pairwise comparison, new GLP-1 RA users were matched in a 1:1 ratio on propensity score to new users of SGLT2is or DPP4is.

Overall, 21,807 pairs of patients treated with a GLP-1 RA versus an SGLT2i and 21,402 pairs of patients treated with a GLP-1 RA versus a DPP4i were included in the analyses. The researchers found that the hazard ratios of suicidal ideation and behaviors were not significantly different for GLP-1 RAs versus SGLT2is (1.07; 95 percent confidence interval, 0.80 to 1.45) or for GLP-1 RAs versus DPP4is (0.94; 95 percent confidence interval, 0.71 to 1.24).

"Among Medicare beneficiaries with T2D, this study found no clear increased risk for suicidal ideation and behaviors with GLP-1 RAs, although estimates were imprecise and a modest adverse effect could not be ruled out," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-17 03:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords